Medical Developments International

European Delays And Tariff Pressures Will Weigh As Potential Emerges

AnalystLowTarget

Not Invested

Community Contributor

Published

02 Sep 25

AnalystLowTarget's Fair Value

AU$0.80

19.4% undervalued

02 Sep

AU$0.65

44.9%

-5.1%

44.9%

-5.1%

You can edit this narrative until Sep 2 10:13 PM. Then, changes will post as Updates.

Author's Valuation

AU$0.819.4% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

AU$0.8

19.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

10.07%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$1.29m

Earnings '28

84.06x

PE Ratio '28

AU$108.17m

Market Cap '28

AU$108.17m

Market Cap '28

112.66m

No. shares '28

AU$0.96

Share Price '28

AU$0.96 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$0.80

Fair Value '25